Enanta Pharmaceuticals, Inc. (ENTA)
13.60
-0.20
(-1.45%)
USD |
NASDAQ |
Aug 28, 16:00
13.58
-0.02
(-0.11%)
After-Hours: 20:00
Enanta Pharmaceuticals Enterprise Value : 388.57M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 388.57M |
| August 27, 2026 | 394.39M |
| August 26, 2026 | 404.58M |
| August 25, 2026 | 402.54M |
| August 24, 2026 | 403.13M |
| August 21, 2026 | 384.78M |
| August 20, 2026 | 374.88M |
| August 19, 2026 | 385.95M |
| August 18, 2026 | 379.83M |
| August 17, 2026 | 366.14M |
| August 14, 2026 | 375.75M |
| August 13, 2026 | 383.91M |
| August 12, 2026 | 385.65M |
| August 11, 2026 | 386.24M |
| August 10, 2026 | 394.68M |
| August 07, 2026 | 393.52M |
| August 06, 2026 | 380.99M |
| August 05, 2026 | 377.50M |
| August 04, 2026 | 380.41M |
| August 03, 2026 | 369.64M |
| July 31, 2026 | 359.45M |
| July 30, 2026 | 371.09M |
| July 29, 2026 | 355.08M |
| July 28, 2026 | 359.74M |
| July 27, 2026 | 363.23M |
| Date | Value |
|---|---|
| July 24, 2026 | 364.69M |
| July 23, 2026 | 369.64M |
| July 22, 2026 | 372.84M |
| July 21, 2026 | 383.32M |
| July 20, 2026 | 375.75M |
| July 17, 2026 | 392.64M |
| July 16, 2026 | 376.63M |
| July 15, 2026 | 377.79M |
| July 14, 2026 | 374.30M |
| July 13, 2026 | 389.73M |
| July 10, 2026 | 391.48M |
| July 09, 2026 | 407.49M |
| July 08, 2026 | 414.48M |
| July 07, 2026 | 407.79M |
| July 06, 2026 | 415.07M |
| July 02, 2026 | 432.54M |
| July 01, 2026 | 422.64M |
| June 30, 2026 | 417.10M |
| June 29, 2026 | 444.52M |
| June 26, 2026 | 429.70M |
| June 25, 2026 | 413.71M |
| June 24, 2026 | 421.56M |
| June 23, 2026 | 431.44M |
| June 22, 2026 | 411.39M |
| June 18, 2026 | 390.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 121.89M |
| AbbVie, Inc. | 515.75B |
| Coherus Oncology, Inc. | 166.67M |
| BridgeBio Pharma, Inc. | 17.65B |
| RenovoRx, Inc. | 66.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.50M |
| Revenue (Quarterly) | 14.36M |
| Total Expenses (Quarterly) | 33.86M |
| EPS Diluted (Quarterly) | -0.6704 |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -17.73% |
| Normalized Earnings Yield | -17.73 |